ATRA · Atara Biotherapeutics, Inc.
$9.44
+0.42 (+4.66%)
At close · Sep 2
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$94.76M
Shares
10.04M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. Former President and Chief Executive Officer | $1,722,332 |
| AnhCo Nguyen | President and Chief Executive Officer | $1,573,716 |
| Eric Hyllengren | — | $926,137 |
| Amar Murugan | — | $878,428 |
| Jill Henrich | — | $812,547 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. Former President and Chief Executive Officer | $4,375,125 |
| Former EVP | Chief Legal Officer | $2,312,153 |
| AnhCo Nguyen | President and Chief Executive Officer | $2,277,691 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,158,127 |
| Charlene Banard | EVP, Chief Technical Officer | $3,201,748 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,117,335 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,285,827 |
| Jakob Dupont | EVP, Global Head of Research and Development | $2,796,245 |
| Kristin Yarema | SVP, Chief Commercial Officer | $2,436,407 |
| Joseph Newell | EVP, Chief Operations Officer | $2,251,063 |
| Utpal Koppikar | Chief Financial Officer | $2,137,953 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. President & Chief Executive Officer | $6,637,307 |
| Joseph Newell | EVP, Chief Operations Officer | $2,719,167 |
| Utpal Koppikar | Chief Financial Officer | $2,540,170 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Isaac Ciechanover M.D | Former President & Chief Executive Officer | $6,132,757 |
| Dietmar Berger | M.D., Ph.D. Former Global Head of Research & Development | $4,972,439 |
| Utpal Koppikar | Chief Financial Officer | $4,220,282 |
| Former SVP | Corporate Strategy and General Counsel | $3,384,425 |
| Joseph Newell | EVP, Chief Operations Officer | $2,492,292 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Joseph Newell | EVP, Chief Technical Operations Officer | $1,815,798 |
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
33 filings
32 filers
Visit website
Investor relations